CJC-1295 no DAC / GHRP-2 Blend
CJC + GHRP-2
CJC-1295 no DAC / GHRP-2 Blend is a pre-mixed growth hormone secretagogue combination pairing Modified GRF(1-29) with Growth Hormone Releasing Peptide-2. This dual-action blend stimulates both the GHRH receptor and the ghrelin receptor simultaneously, producing amplified pulsatile GH release that exceeds either peptide alone. It is one of the most widely available GH blends from compounding pharmacies.
Starting dose. 100mcg — CJC / 100mcg GHRP-2 per injection
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
This blend works through dual-receptor stimulation of the GH axis:
CJC-1295 no DAC (Mod GRF 1-29)
Binds GHRH receptors on pituitary somatotrophs, activating cAMP/PKA signaling to prime GH granule release. The four amino acid substitutions protect against DPP-IV degradation while preserving full receptor activity. Without the DAC linker, it produces acute GH pulses with a ~30 minute half-life.
GHRP-2 (Pralmorelin)
Binds GHS-R1a (ghrelin receptor) on the pituitary, triggering GH release through a separate intracellular pathway (PLC/IP3/PKC). Also suppresses somatostatin, removing the natural brake on GH secretion. Stimulates appetite via hypothalamic ghrelin signaling - moderate compared to GHRP-6.
Synergistic Amplification
The GHRH signal (CJC) and GHRP signal (GHRP-2) converge on somatotrophs through independent pathways, producing GH pulses 3-5x greater than either peptide alone. This mimics the natural dual-signal system the body uses for GH regulation.
What to expect
Days 1-7: Noticeable appetite increase after injection. Improved sleep quality, especially deeper sleep and vivid dreams. Possible mild water retention. Flushing or tingling post-injection is common and harmless.
Weeks 2-6: Body composition changes becoming visible. Improved skin quality and elasticity. Recovery from training noticeably faster. Fat loss in midsection area. Appetite effect becomes more predictable and manageable.
Weeks 6-12: Full body recomposition effects evident. Lean mass gains consolidated. Skin and hair improvements. Sleep architecture optimized. Consider cycling off after 12 weeks to maintain pituitary sensitivity.
Evidence
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: 100 mcg CJC + 100 mcg GHRP-2 SubQ 2-3 times daily while fasted. No checked abstract administered this exact fixed combination, ratio, SubQ dose, or frequency in humans.
Mechanism and claimed 3-5× GH-pulse synergy for the exact blend. Component and GHRH/GHRP class evidence cannot establish the magnitude, formulation, or pharmacodynamics of this exact no-DAC fixed blend.
Primary safety concern, including cortisol/prolactin effects above 200 mcg. No checked human abstract evaluated safety of the exact fixed blend at the displayed regimen; component-only safety was not transferred.
The honest take
GHRP-2 is approved in Japan as Pralmorelin for clinical use
Partly truePartially accurate. GHRP-2 (pralmorelin) is approved in Japan specifically as a diagnostic agent for GH deficiency testing, not as a therapeutic drug for GH optimization. The approval confirms safety for single-dose administration.
Well-supported by comparative human studies. GHRP-2 produces noticeable but manageable hunger, consistently rated between Ipamorelin (minimal appetite effect) and GHRP-6 (strong hunger drive) in clinical observations.
Dose-dependent. At 100mcg, cortisol and prolactin increases are generally subclinical. Above 200mcg per injection, these elevations become more meaningful. Keeping doses at or below 200mcg GHRP-2 per injection is recommended to minimize this.
Interactions & stacking
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Documented together
Keep separate
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
Side effects & safety
Commonly reported
- Moderate appetite increase (15-30 min post-injection, lasts ~1 hour)
- Flushing or warmth post-injection (transient, harmless)
- Mild water retention in first 1-2 weeks
- Tingling or numbness in extremities post-injection
- Vivid dreams or disrupted sleep initially
Less common & notes
- At higher GHRP-2 doses (above 200mcg), mild cortisol and prolactin elevation may occur.
- Symptoms could include slight anxiety or irritability post-injection.
- Rarely, mild headache or lethargy.
- These effects are dose-dependent and resolve by reducing the GHRP-2 component.
- Keep individual GHRP-2 doses at or below 200mcg to minimize these hormonal side effects.
Pharmacokinetics
CJC-1295 no DAC: ~30 min; GHRP-2: ~25 min. Combined GH pulse duration: 1.5-2 hours.
CJC: 15-30 min; GHRP-2: 15-20 min. Peak synergistic GH release at ~20-30 min post-injection.
Both components cleared within 2-3 hours. GH pulse elevation returns to baseline by 3-4 hours.
SubQ: ~95-100% for both components. Oral: not viable (peptide degradation in GI tract).
GH pulse lasts 1.5-2 hours. Downstream IGF-1 elevation persists 12-20 hours. Appetite effect from GHRP-2 lasts ~1 hour post-injection.
Enzymatic degradation by peptidases. CJC modifications provide DPP-IV resistance. GHRP-2 cleared primarily by renal and hepatic peptidases.
Storage. Store lyophilized vial at room temperature or refrigerated. After reconstitution with bacteriostatic water, store refrigerated at 2-8C. Use within 28-30 days of reconstitution. Do not freeze after reconstitution. Protect from light. Discard if solution becomes cloudy or contains particulate matter.
Regulatory status
Not FDA-approved. Available through compounding pharmacies with prescription. GHRP-2 (pralmorelin) has been studied in clinical trials in Japan and other countries for GH deficiency diagnosis. CJC-1295 no DAC (Mod GRF 1-29) has human pharmacokinetic data. Pre-mixed blends are a compounding pharmacy product. Classified as research peptides in most jurisdictions. All use is experimental/off-label.
Put it to work
Calculate, log & track
Open CJC-1295 no DAC / GHRP-2 Blend straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open CJC-1295 no DAC / GHRP-2 Blend in the app →Go deeper
The guide & community
The complete CJC-1295 no DAC / GHRP-2 Blend walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗